August 11, 2025 Second Quarter 2025 Financial Results & Business Update On Today's Call • Welcome Brendan Strong, SVP, Investor Relations and Corporate Communications • Overview Richard Paulson, President and Chief Executive Officer • Pipeline Update Dr. Reshma Rangwala, Chief Medical Officer and Head of Research • Commercial Highlights Sohanya Cheng, Chief Commercial Officer and Head of Business Development ©2025 KARYOPHARM THERAPEUTICS INC. 2 • Financial Results and Guidance Lori Macomber, Chief Financial ...

Q2'25 Financial Highlights - Revenue reached $2.4 billion, a 14% increase LFL(Like-for-like) [10] - Adjusted EBITDA was $137 million, up 12% LFL [10] - Adjusted Diluted EPS stood at $0.55, reflecting a 9% increase [10] Segment Performance - Fresh Fruit revenue increased by 14.2% to $972 million [32, 35], with Adjusted EBITDA up by 3% to $72.7 million [32, 35] - Diversified Fresh Produce – EMEA saw a revenue increase of 16.5% to $1.101 billion [37, 40], with Adjusted EBITDA up 14.7% to $49 million [37, 40] - Diversified Fresh Produce – Americas & ROW experienced an 8.5% increase in revenue to $386 million [42, 45], and Adjusted EBITDA increased by 27% to $15.4 million [42, 45] Capital Allocation and Debt - Cash CAPEX for continuing operations was $(19.4) million in Q2'25 and $(72.2) million in H1'25 [46] - Free Cash Flow from continuing operations was $(1.0) million in Q2'25 and $(132.6) million in H1'25 [46] - Net Debt stood at $(788.8) million with a Net Leverage of 2.0x as of June 30, 2025 [47] FY'25 Outlook - The company anticipates Adjusted EBITDA for continuing operations to be approximately $380 - $390 million [51] - Maintenance CAPEX for continuing operations is projected to be around $100 million [51] - Interest expense is expected to be approximately $67 million [51]

Business Highlights - Roivant completed a $1.5 billion share repurchase program in June 2025, repurchasing approximately 149 million shares at an average price of $10.09, reducing the share count by over 15%[23] - The company expanded its pipeline by initiating 6 potentially registrational studies and 3 proof-of-concept (POC) studies[23] - Roivant increased shareholder exposure to clinical and litigation catalysts over the next 36 months[23] Brepocitinib Program - Topline data from the Phase 3 VALOR study of brepocitinib in dermatomyositis (DM) is expected in the second half of 2025[20, 27] - The VALOR study enrolled 241 adults with active DM, with 38% from the US, 32% from the EU, and 30% from the rest of the world[35] - Approximately 40% of subjects taking oral corticosteroids (OCS) at baseline in the VALOR study were able to eliminate OCS entirely by the end of the study[45] LNP Litigation - Summary judgment phase is ongoing in the US Moderna case, with a jury trial scheduled for March 2026[18, 27, 52] - Ongoing progress is expected in the Pfizer/BioNTech case following the Markman hearing, with a decision potentially in 2025[18, 27, 52] Financial Update - Research and development (R&D) expense was $153 million, with an adjusted R&D expense of $141 million (non-GAAP)[58] - General and administrative (G&A) expense was $134 million, with an adjusted G&A expense of $63 million (non-GAAP)[58] - Roivant had $4.5 billion in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2025[58]

Financial Performance - Plus500 announced shareholder returns of $365 million in YTD 2025[8] - Total shareholder returns since IPO in 2013 reached $2.7 billion[10] - H1 2025 revenue increased by 4% to $415.1 million compared to $398.2 million in H1 2024[107, 114] - EBITDA for H1 2025 grew by 1% to $185.1 million from $183.9 million in H1 2024[107, 114] - The company maintains a strong balance sheet with cash balances of over $0.9 billion and no debt[49, 72] Customer Metrics - Average deposit per active customer increased by 105% to approximately $17,250 in H1 2025[14, 107] - Active customers increased by 2% to 179,931 in H1 2025[52, 107] - 89% of OTC revenue in H1 2025 was generated through mobile and tablet offerings[14, 99] - 66% of OTC revenue was derived from customers trading with Plus500 for over three years[14] Strategic Growth - Non-OTC revenue is anticipated to be more than $100 million in FY 2025[61] - Customer segregated funds in the US futures market reached approximately $850 million as of June 30, 2025[67]

KT 2Q25 Earnings Release Disclaimer This presentation has been prepared by KT Corp.(the "Company") in accordance with K-IFRS. This presentation contains forward-looking statements, which are subject to risks, uncertainties, and assumptions. This presentation is being presented solely for your information and is subject to change without notice. No presentation or warranty, expressed or implied, is made and no reliance should be placed on the accuracy, actuality, fairness, or completeness of the information ...

Financial Performance (H1/2025) - Revenues reached €1,835.9 million[11] - EBITDA amounted to €310.3 million, with an EBITDA margin of 16.9%[11] - Adjusted free cash flow was €24.3 million[11] Potash Market and Production - K+S expects potash demand to grow at a compound annual growth rate of 2-3%[14] - The company aims to increase potash production by >100,000 tonnes per year at the Bethune plant in Canada[14] - K+S Germany potash production capacity is approximately 5.5 million tonnes eff[194] Salt Market and Production - K+S has a 20% market share in the European salt market[65, 66] - K+S Germany salt production capacity is approximately 5 million tonnes eff[196] Sustainability and Environmental Goals - K+S has reduced CO2 emissions by around 80% since 1990[17] - The company aims for greenhouse gas neutrality at its production sites by 2045, with a 25% CO2 emissions reduction by 2030 compared to 2020[17, 101] - K+S is targeting a 25% reduction in absolute CO2 emissions by 2030, with a 4.4% reduction achieved by 2024 (base year 2020)[106, 145] Agriculture Segment (H1/2025) - Agriculture segment revenues were €1,282.3 million[20] - Sales volumes for the agriculture segment reached 3.84 million tonnes[20] Industry+ Segment (H1/2025) - Industry+ segment revenues were €553.6 million[22] - Sales volumes for the Industry+ segment reached 3.12 million tonnes, including 0.88 million tonnes of de-icing salt[22, 166]

Financial Performance - FY25 FFO was 20.7 cents per security, slightly above the guidance of 20.6 cents per security[17] - Distributions were also 20.7 cents per security[17] - Net property income was $46.445 million in FY25 compared to $48.350 million in FY24[74] - Portfolio valuation increased by $16.6 million, representing a 2.3% increase[41] - NTA per security increased by 2.2% from $3.56 to $3.64[32] Portfolio and Operations - Portfolio occupancy remained high at 99.9%[12] - The portfolio Weighted Average Lease Expiry (WALE) is 7.9 years[12] - Like-for-like income growth was +2.9%[17] - Average rent review achieved +3.1%[17] - $38.8 million of strategic divestments were executed[15] Capital Management - Gearing was 29.4%, at the lower end of the target range of 25-40%[14] - Average debt hedged was 72%[14] - Total borrowings amounted to $215.5 million[35] Future Outlook - FY26 FFO and distributions are expected to be 20.9 cents per security, reflecting growth of 1.2%[54]

Project Overview - Colossus project boasts a world-class global resource of 493 million tonnes @ 2,508 ppm TREO and 601 ppm MREO [16] - The Measured & Indicated resource stands at 329 million tonnes @ 659 ppm MREO, recognized as the highest grade MREO IAC resource globally [16] - The project covers only 11% of the total landholding (28km2 of 261 km2), indicating significant exploration upside [16, 20] Metallurgical Performance - The project achieves industry-leading "Resource to MREC" recovery rates of 76% MREO in the Northern Concessions and 78% MREO in the Southern Complex [16] - The metallurgical process uses 0.3M Ammonia Sulphate at pH 4.5 and room temperature [16] Economic Viability - The Pre-tax NPV8 is US $1.41 billion (AUD 2.13 billion) with an IRR of 43%, based on a US $90/kg NdPr price [16] - The project is positioned as a lowest-cost REE producer globally, with C1 OPEX of US $6.2/kg TREO and CAPEX of US $286 million (excluding contingency) for a 5Mtpa facility [16] - The LOM average TREO Recovery is 57%, and the LOM average MREO Recovery is 76% [38] Strategic Partnerships and Funding - The company has secured funding support of up to approximately AU$58.5 million [16] - A JV has been established with Ionic Rare Earths (ASX:IXR) for REO separation and refining technology [16]

Company Overview - Green 360 Technologies Limited (ASX:GT3) is an Australian-based building materials company focused on developing low-cost, low-carbon cement[1, 13] - The company has kaolin assets providing an immediate revenue stream and strong financial foundation[13] - As of August 6, 2025, the company's market capitalization was approximately $32.30 million, with a share price of $0.032[58] - The company's cash and cash equivalents as of June 30, 2025, were $1.8 million[58] Market Opportunity and Product - The global cement market is forecasted to reach $673.8 billion by 2033, with a CAGR of approximately 4.7%[18] - The global concrete market is forecasted to reach $617.3 billion by 2030, with a CAGR of approximately 5.2%[18] - Traditional cement production accounts for 8% of global CO2 emissions, or 3.2 billion tonnes of CO2 per year[20] - The company's low-carbon cement is designed as a "drop-in solution," offering a low-cost, low-carbon alternative with superior performance and a reduced environmental footprint[13] Operations and Revenue Generation - The company generated $13.3 million in revenue in FY25 from the sale of approximately 22kt of kaolin product[42] - The Pittong Kaolin Operation has multi-decade mine life, supported by over 18Mt total of Inferred and Indicated JORC Compliant Kaolin Resources[42] - The company is undertaking a capital raising to raise A$4.0 million via a placement of 181,818,181 new shares at $0.0220 per share[63]

Company Overview - Westwood Holdings Group is an asset management firm offering investment strategies and wealth services[5] - The firm's Assets Under Management (AUM) totaled $18.3 billion as of June 30, 2025, including $17.3 billion in AUM and $0.9 billion in Assets Under Advisement (AUA)[7, 20] - Employees and directors own approximately 33% of the company's equity[6] Investment Strategies and Asset Allocation - U S Value Equity accounts for 51% of the firm's strategy breakdown[12] - Multi-Asset/Multi-Strategy represents 28% of the strategy breakdown[12] - Wealth strategy makes up 21% of the strategy breakdown[12] Client Base - Institutional Separate Accounts & Other Managed Accounts comprise 53% of assets by account type[12] - Wealth Management accounts for 24% of assets by account type[12] - Westwood Mutual Funds & ETFs represent 23% of assets by account type[12] Diversity and Inclusion - Women make up 41% of the company's employees[16] - Women hold 43% of the corporate board member positions[16] Financial Performance - The company's revenues for Q2 2025 were $23.1 million[20] - The company reported income of $1.0 million for Q2 2025[20]